Dabigatran

Dabigatran (CAS 211914-51-1), also referenced under the development code BIBR-953, is a direct thrombin inhibitor used as an active pharmaceutical ingredient in anticoagulant drug development. It functions as the pharmacologically active moiety in oral anticoagulant formulations targeting thromboembolic conditions. Dabigatran is the active ingredient in finished dosage form development for stroke prevention and venous thromboembolism treatment, typically formulated as the etexilate prodrug salt for oral bioavailability.

Pharmaceutical manufacturers source it as a reference standard or synthetic intermediate during API characterization, method validation, and quality control workflows. Research institutions and contract development organizations use it in pharmacokinetic studies. It also serves as a benchmark compound in assay development for thrombin inhibition screening programs. Supplied as a solid powder, it is available in research-grade and pharmaceutical-grade specifications suited to analytical and development applications.

Purity grades aligned with reference standard requirements are the most commonly sourced forms in the B2B market. Packaging ranges from milligram quantities for laboratory use to larger quantities supporting API development pipelines. Our supply chain ensures that the material meets rigorous internal quality benchmarks. This product is intended for laboratory research and pharmaceutical manufacturing purposes only, ensuring consistency across various batch requirements.